12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zelboraf vemurafenib: Phase III started

In its 3Q12 earnings, Roche said that it began the 52-week, placebo-controlled Phase III BRIM8 trial evaluating adjuvant therapy with 960 mg Zelboraf twice daily in 725 patients with resected cutaneous BRAF mutation-positive melanoma. Zelboraf is...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >